Patents by Inventor Daniel R. Weinberger

Daniel R. Weinberger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Schizophrenia-related isoform of KCNH2 and development of antipsychotic drugs
    Patent number: 8871443
    Abstract: The invention is related to a novel primate specific brain isoform of the potassium channel KCNH2 and genetic association with risk for schizophrenia and response to therapy.
    Type: Grant
    Filed: January 24, 2012
    Date of Patent: October 28, 2014
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventor: Daniel R. Weinberger
  • SCHIZOPHRENIA-RELATED ISOFORM OF KCNH2 AND DEVELOPMENT OF ANTIPSYCHOTIC DRUGS
    Publication number: 20120190558
    Abstract: The invention is related to a novel primate specific brain isoform of the potassium channel KCNH2 and genetic association with risk for schizophrenia and response to therapy.
    Type: Application
    Filed: January 24, 2012
    Publication date: July 26, 2012
    Applicant: THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES
    Inventor: Daniel R. WEINBERGER
  • Schizophrenia-related isoform of KCNH2 and development of antipsychotic drugs
    Patent number: 8101380
    Abstract: The invention is related to a novel primate specific brain isoform of the potassium channel KCNH2 and genetic association with risk for schizophrenia.
    Type: Grant
    Filed: March 21, 2008
    Date of Patent: January 24, 2012
    Assignee: The United States of America as represented by the Secretary of Health and Human Services
    Inventors: Daniel R. Weinberger, Stephen J. Huffaker, Joel E. Kleinman, Bai Lu
  • PHOSPHATIDYLINOSITOL-3-KINASE P110 DELTA-TARGETED DRUGS IN THE TREATMENT OF CNS DISORDERS
    Publication number: 20110294803
    Abstract: Methods for treating CNS disorders such as schizophrenia, psychosis and cognitive disorders using specific inhibitors of phosphatidylinositol-3-kinase p110 delta (PIK3CD) expression and/or activity are described. Methods of determining risk of CNS disorders and methods of determining treatment response are also described. An integrative systems biology approach to identify a signaling mechanism and genetic network associated with schizophrenia and with schizophrenia-associated risk variation in ErbB4. A risk pathway associated with ErbB4 genetic variation involving increased expression of a PI3K-linked ErbB4 receptor CYT-1 and a specific PI3K enzyme, PIK3CD has been identified.
    Type: Application
    Filed: December 4, 2009
    Publication date: December 1, 2011
    Inventors: Amanda J. Law, Daniel R. Weinberger
  • SCHIZOPHRENIA-RELATED ISOFORM OF KCNH2 AND DEVELOPMENT OF ANTIPSYCHOTIC DRUGS
    Publication number: 20100105623
    Abstract: The invention is related to a novel primate specific brain isoform of the potassium channel KCNH2 and genetic association with risk for schizophrenia.
    Type: Application
    Filed: March 21, 2008
    Publication date: April 29, 2010
    Applicant: THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICE
    Inventors: Daniel R. Weinberger, Stephen J. Huffaker, Joel E. Kleinman, Bai Lu
  • Effect of COMT genotype on frontal lobe function
    Publication number: 20030100476
    Abstract: The invention provides a method of detecting impaired prefrontal cognitive function in an individual by determining the individual's COMT genotype, and associating a high activity Val allele with impaired prefrontal cognitive function (and a low activity Met allele with enhanced prefrontal cognitive function).
    Type: Application
    Filed: May 10, 2002
    Publication date: May 29, 2003
    Inventors: Daniel R. Weinberger, Michael F. Egan, Terry E. Goldberg, Joseph H. Callicott, David Goldman
  • Stannylated 3-quinuclidinyl benzilates and methods of preparing radiohalogenated derivatives
    Patent number: 5569447
    Abstract: The present invention provides stannylated 3-quinuclidinyl benzilate compounds and a method of synthesizing *AQNB by iodinating such stannylated 3-quinuclidinyl benzilate compounds. The iodination of these stannylated 3-quinuclidinyl benzilates proceeds in as little as five minutes; thus, the stannylated 3-quinuclidinyl benzilates may be converted to *AQNB in situ for immediate use. Using this method, radiolabelling yields as high as 80% have been observed. The present invention also is directed towards a method of synthesis of the stannylated 3-quinuclidinyl benzilate compounds. The method comprises providing a 4'-halo-3-quinuclidinyl benzilate and reacting the 4'-halo-3-quinuclidinyl benzilate with a compound having the formula (SnR.sub.3).sub.2, wherein R is an alkyl.
    Type: Grant
    Filed: April 19, 1994
    Date of Patent: October 29, 1996
    Assignee: The United States of America represented by the Secretary Department of Health and Human Services
    Inventors: Kan S. Lee, Xiao-Shu He, Daniel R. Weinberger
  • Rat or mouse exhibiting behaviors associated with human schizophrenia
    Patent number: 5549884
    Abstract: This invention provides a unique and surprisingly accurate animal model for human schizophrenia. The animals are brain damaged while prepubescent. The brain damage consists of a ventral hippocampus lesion induced by exposure of the hippocampus region to a neurotoxin. When the animal reaches puberty, abnormal behavior and a number of biological phenomena associated with schizophrenic symptoms emerge. These animals are useful for assaying pharmaceutical compounds for anti-schizophrenic activity.
    Type: Grant
    Filed: October 28, 1992
    Date of Patent: August 27, 1996
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Daniel R. Weinberger, Barbara K. Lipska, George E. Jaskiw